Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy

Current Treatment Options in Oncology
Andrew J StephensonJames Eastham

Abstract

The greatest obstacle in the cure of patients with locally recurrent prostate cancer after radiation therapy is the lack of early detection markers. The majority of patients who are candidates for local salvage therapy have locally advanced disease, precluding successful salvage therapy. A low pretreatment prostate specific antigen (PSA) has shown to be a favorable prognostic variable for disease progression, regardless of the specific local salvage therapy used. Of all the local salvage treatment options for these patients, we believe that salvage radical prostatectomy (RP) offers patients the greatest likelihood of a cure. The salvage RP results approach those achieved with standard RP for patients of similar pathologic stage. When patients are treated early in the course of recurrent disease (preoperative PSA < 10 ng/mL), an estimated two-thirds of patients will be disease-free 5 years after salvage RP alone. With better patient selection and continued technical modifications, the morbidity associated with salvage RP has substantially improved. Perioperative complications approach those observed with standard RP and approximately two-thirds of patients will recover urinary continence. Select patients may also recover functio...Continue Reading

References

Mar 1, 1992·The Journal of Urology·T E AhleringD G Skinner
Aug 30, 1995·International Journal of Radiation Oncology, Biology, Physics·G K ZagarsA C von Eschenbach
Dec 1, 1993·The Journal of Urology·P F SchellhammerA M el-Mahdi
Feb 1, 1993·Cancer·J E PontesR Huben
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W R LeeA Hanlon
May 1, 1997·The Journal of Urology·O DillioglugilP T Scardino
Jul 4, 1998·International Journal of Radiation Oncology, Biology, Physics·M J ZelefskyZ Fuks
May 11, 1999·JAMA : the Journal of the American Medical Association·C R PoundP C Walsh
May 11, 1999·JAMA : the Journal of the American Medical Association·W U ShipleyC D Smith
Jul 20, 1999·The Journal of Urology·P PerrotteL L Pisters
May 8, 2000·The Journal of Urology·J W Moul
Oct 6, 2000·International Journal of Radiation Oncology, Biology, Physics·H M SandlerJ M Taylor
Jun 29, 2001·International Journal of Radiation Oncology, Biology, Physics·A L HanlonG E Hanks
Jun 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonathan I IzawaLouis L Pisters
Nov 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony V D'AmicoDelray Schultz
Oct 9, 2003·The Journal of Urology·Guy VallancienFrançois Rozet
Oct 25, 2003·International Journal of Radiation Oncology, Biology, Physics·Deborah A KubanAnthony L Zietman
Feb 21, 2004·CA: a Cancer Journal for Clinicians·Ahmedin JemalUNKNOWN American Cancer Society
Feb 2, 2010·International Journal of Radiation Oncology, Biology, Physics·Kathryn Beal, Beryl McCormick

❮ Previous
Next ❯

Citations

Mar 8, 2007·Journal of the National Cancer Institute·Simon A WilliamsSamuel R Denmeade
May 18, 2010·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·P PaparelUNKNOWN membres du sous-comité prostate du CCAFU
Jun 29, 2013·Seminars in Oncology·Nicholas G ZaorskyRobert B Den
Nov 6, 2012·Radiologic Clinics of North America·Jurgen J Fütterer
Mar 17, 2012·European Urology·Vladimir MouravievJ Stephen Jones
Jan 27, 2010·Cancer Treatment Reviews·Christian Boukaram, Jean-Michel Hannoun-Levi
May 30, 2006·Hematology/oncology Clinics of North America·Joycelyn L Speight, Mack Roach
Jan 24, 2009·Journal of Magnetic Resonance Imaging : JMRI·Chan Kyo KimHyun Moo Lee
Jul 9, 2009·BJU International·Masaki KimuraThomas J Polascik
Aug 27, 2013·European Urology·David PfisterMichael J Zelefsky
Apr 8, 2017·Clinical Radiology·D A WoodrumL A Mynderse
Jun 6, 2018·Topics in Magnetic Resonance Imaging : TMRI·David A WoodrumLance A Mynderse
May 22, 2007·BJU International·Andrew K Lee, Anthony V D'Amico
Aug 9, 2017·Expert Review of Anticancer Therapy·D LipmanTheo M De Reijke

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.